Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs
- Health and wellness drug bio-effectiveness innovator Lexaria Bioscience is advancing human testing of its patented DehydraTECH(TM) technology for the potential treatment of high blood pressure and heart disease
- Lexaria also recently announced that DehydraTECH boosted the speed and effectiveness of sildenafil in laboratory rats for the potential treatment of erectile dysfunction (“ED”)
- The company’s statement notes that DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation”
- ED affects some 30 million men in the United States and is expected to affect about 322 million men worldwide by 2025
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has made a case for increasing the rapidity and effectiveness of medication absorption through Lexaria’s patented DehydraTECH(TM) technology. Recent clinical studies have shown the potential for improved bio-effectiveness of nicotine and cannabidiol (“CBD”) when processed with DehydraTECH for the potential treatment of conditions such as high blood pressure and arterial stiffness, for example.
In a Feb. 2 news release, the company announced it has also observed successes when administering DehydraTECH-processed sildenafil to lab rats to study the potential of Lexaria technology in improving the treatment of erectile dysfunction.
Viagra, the most widely known sildenafil product in the world, “is moderately bioavailable orally at roughly 40%, but many people find it slow to act,” Lexaria’s news release states (https://nnw.fm/n0AEk). The company’s PDE5-A21-1 animal study found DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation.”
The study suggests sildenafil may take effect much more quickly when processed with DehydraTECH than without it. Seven minutes after the animals received their doses, the DehydraTECH-sildenafil formulation reached an average blood level higher than the generic sildenafil control formulation reached at any point during the study, the company states.
The landmark Massachusetts Male Aging Study completed in 1994 reported that 52 percent of men experience some form of erectile dysfunction (“ED”), while other more recent studies have found that about 30 million men in the United States may be affected, with about 322 million men worldwide expected to be affected by 2025 (https://nnw.fm/seLsG).
Lexaria’s study could be a boon for Viagra or its generic pharmaceutical competitors in responding to the market for ED solutions that are faster and more effective than current options. The company noted that despite a clear trend toward faster and higher overall delivery of sildenafil into the bloodstream, the improvements in delivery rate did not achieve statistical significance so further investigation with a larger number of animals may be needed.
In the meantime, human clinical studies evaluating DehydraTECH’s potential for treating hypertension in combination with CBD are ongoing. In December, the U.S Food and Drug Administration (“FDA”)-registered Independent Review Board (“IRB”) approved the protocols for HYPER-H21-4, which is tentatively expected to begin dosing by April to measure 24-hour ambulatory blood pressure (the primary outcome), blood biomarkers (including lipids such as cholesterol), sleep disorders and perceived stress (https://nnw.fm/iVnrx).
These markers will provide information on DehydraTECH-CBD’s impact on chronic heart disease, following on the positive results of the blood pressure studies.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Health and wellness drug bio-effectiveness innovator Lexaria Bioscience is advancing human testing of its patented DehydraTECH(TM) technology for the potential treatment of high blood pressure and heart disease
- Lexaria also recently announced that DehydraTECH boosted the speed and effectiveness of sildenafil in laboratory rats for the potential treatment of erectile dysfunction (“ED”)
- The company’s statement notes that DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation”
- ED affects some 30 million men in the United States and is expected to affect about 322 million men worldwide by 2025
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has made a case for increasing the rapidity and effectiveness of medication absorption through Lexaria’s patented DehydraTECH(TM) technology. Recent clinical studies have shown the potential for improved bio-effectiveness of nicotine and cannabidiol (“CBD”) when processed with DehydraTECH for the potential treatment of conditions such as high blood pressure and arterial stiffness, for example.
In a Feb. 2 news release, the company announced it has also observed successes when administering DehydraTECH-processed sildenafil to lab rats to study the potential of Lexaria technology in improving the treatment of erectile dysfunction.
Viagra, the most widely known sildenafil product in the world, “is moderately bioavailable orally at roughly 40%, but many people find it slow to act,” Lexaria’s news release states (https://nnw.fm/n0AEk). The company’s PDE5-A21-1 animal study found DehydraTECH-processed sildenafil “delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation.”
The study suggests sildenafil may take effect much more quickly when processed with DehydraTECH than without it. Seven minutes after the animals received their doses, the DehydraTECH-sildenafil formulation reached an average blood level higher than the generic sildenafil control formulation reached at any point during the study, the company states.
The landmark Massachusetts Male Aging Study completed in 1994 reported that 52 percent of men experience some form of erectile dysfunction (“ED”), while other more recent studies have found that about 30 million men in the United States may be affected, with about 322 million men worldwide expected to be affected by 2025 (https://nnw.fm/seLsG).
Lexaria’s study could be a boon for Viagra or its generic pharmaceutical competitors in responding to the market for ED solutions that are faster and more effective than current options. The company noted that despite a clear trend toward faster and higher overall delivery of sildenafil into the bloodstream, the improvements in delivery rate did not achieve statistical significance so further investigation with a larger number of animals may be needed.
In the meantime, human clinical studies evaluating DehydraTECH’s potential for treating hypertension in combination with CBD are ongoing. In December, the U.S Food and Drug Administration (“FDA”)-registered Independent Review Board (“IRB”) approved the protocols for HYPER-H21-4, which is tentatively expected to begin dosing by April to measure 24-hour ambulatory blood pressure (the primary outcome), blood biomarkers (including lipids such as cholesterol), sleep disorders and perceived stress (https://nnw.fm/iVnrx).
These markers will provide information on DehydraTECH-CBD’s impact on chronic heart disease, following on the positive results of the blood pressure studies.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
